Suggested Reading

On Malignant Pleural Effusion

Akamatsu H, Koh Y, Kenmotsu H, et al: Multiplex molecular profiling of lung cancer using pleural effusion. J Thorac Oncol 9:1048–1052, 2014.

Balassoulis G, Sichletidis L, Spyratos D, et al: Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol 31:384–389, 2008.

Basso SM, Mazza F, Marzano B, et al: Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results. Anticancer Res 32:5131–5134, 2012.

Bhattacharya S, Bairagya TD, Das A, et al: Closed pleural biopsy is still useful in the evaluation of malignant pleural effusion. J Lab Physicians 4:35–38, 2012.

Boshuizen RC, Onderwater S, Burgers SJ, et al: The use of indwelling pleural catheters for the management of malignant pleural effusion - direct costs in a Dutch hospital. Respiration 86:224–228, 2013.

Boshuizen RC, Sinaasappel M, Vincent AD, et al: Pleural pressure swing and lung expansion after malignant pleural effusion drainage: the benefits of high-temporal resolution pleural manometry. J Bronchology Interv Pulmonol 20:200–205, 2013.

Bradshaw M, Mansfield A, Peikert T: The role of vascular endothelial growth factor in the pathogenesis, diagnsosis and treatment of malignant pleural effusion. Curr Oncol Rep 15:207–216, 2013.

Bugalho A, Ferreira D, Dias SS, et al: The diagnostic value of transthoracic ultrasonographic features in predicting malignancy in undiagnosed pleural effusions: A prospective observational study. Respiration 87:270–278, 2014.

Cavanna L, Mordenti P, Berte R, et al: Ultrasound guideance reduces pneumothorax rate and improves safety of thoracentesis in malignant pleural effusion: Report on 445 consecutive patients with advanced cancer. World J Surg Oncol 12:139, 2014.

Chen WJ, Yuan SF, Yan QY, et al: Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: A randomized prospective study. Cancer Invest 30:126–130, 2012.

Clive AO, Kahan BC, Hooper CE, et al: Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score. Thorax 69:1098–1104, 2014.

Damianovich M, Siloni GH, Barshack I, et al: Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion. Clin Lung Cancer 14:688–698, 2013.

Davies HE, Mishra EK, Kahan BC, et al: Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. JAMA 307:2383–2389, 2012.

Davies HE, Nicholson JE, Rahman NM, et al: Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg 38:472–477, 2010.

Dresler CM, Olak J, Herndon JE 2nd, et al: Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127:909–915, 2005.

Du N, Li X, Li F, et al: Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep 29:2332–2340, 2013.

Du Rand I, Maskell N, eds: British Thoracic Society Pleural Disease Guideline 2010. Thorax 65(Suppl 2):ii1–ii76, 2010.

Fiorelli A, Santini M: In lung cancer patients where a malignant pleural effusion is found at operation could resection ever still be justified? Interact Cardiovasc Thorac Surg 17:407–412, 2013.

Freeman RK, Ascioti AJ, Mahidhara RS: A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy. Ann Thorac Surg 96:259–263, 2013.

Fysh ET, Tan SK, Read CA, et al: Pleurodesis outcome in malignant pleural mesothelioma. Thorax 68:594–596, 2013.

Galbis JM, Mata M, Guijarro R, et al: Clinical-therapeutic management of thoracoscopy in pleural effusion: A groundbreaking technique in the twenty-first century. Clin Transl Oncol 13:57–60, 2011.

Gonzalez AV, Bedwada V, Beamis JF Jr, et al: Lung injury following thoracoscopic talc insufflation: Experience of a single North American center. Chest 137:1375–1381, 2010.

Guo H, Wan Y, Tian G, et al: EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. Oncol Rep 27:880–890, 2012.

Gross JL, Disanzio TG, Younes RN, et al: Do concomitant ascites influence the effectiveness of palliative surgical management of pleural effusion in patients with malignancies? World J Surg 33:266–271, 2009.

Hooper C, Laurence I, Harvey J, et al: The role of CT pulmonary angiography in the investigation of unilateral pleural effusions. Respiration 87:26-31, 2014.

Hsu LH, Soong TC, Feng AC, et al: Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. J Thorac Oncol 1:460–467, 2006.

Kakuda JT, Karamanoukian R, Grannis FW Jr: The utility and safety of an indwelling catheter system (PleurX) to manage malignant pleural effusions. Chest 122:165s, 2002.

Kaneda M, Yokoi K, Ito S, et al: The value of pleural lavage cytology examined during surgery for primary lung cancer. Eur J Cardiothorac Surg 41:1335–1341, 2012.

Kim S, Kim TM, Kim DW, et al: Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-arranged lung cancer. J Thorac Oncol 8:415–422, 2013.

Lee P, Light R: Point/Counterpoint Editorials. Should thoracoscopic talc pleurodesis be the first choice management for malignant effusion? Chest 142:15–21, 2012.

Letovanec I, Allenbach G, Mihaescu A, et al: 18F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer. A cytopathological correlation. Nuklearmedizin 51:186–193, 2012.

Lombardi G, Nicoletto MO, Gusella M, et al: Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: A phase II study with pharmacokinetic analysis. Cancer Chemother Pharmacol 69:781–787, 2012.

Marshall MB, Choong CKC, eds: Management of benign and malignant pleural effusions [monograph]. Thorac Surg Clin 23:1–101, 2013.

Metintas M, Ak G, Dundar E, et al: Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest 137:1362–1368, 2010.

Morgensztern D, Waqar S, Subramanian J, et al: Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol 7:1485–1489, 2012.

Ost DE, Jiminez CA, Lei X, Cantor SB, et al: Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest 2014;145:1347-56.

Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling catheter vs. talc pleurodesis for malignant effusion. Chest 2014; 146:991-1000.

Pichelmayer o, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Ann Oncol 2006, 17:1853.

Puri V, Pyrdeck TK, Crabtree TD, et al: Treatment of malignant pleural effusion: A cost-effectiveness analysis. Ann Thorac Surg 94:374–380, 2012.

Rintoul RC, Ritchie AJ, Edwards JG, et al; MesoVATS Collaborators: Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 2014 ;384:1118-27.

Ryu HJ, Lee SN, Memon A, Lee SK, et al: Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. J Clin Oncol 2014;32:960-7.

Sabur NF, Chee A, Stather DR, et al: The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions. Respiration 85:36–42, 2013.

Sakr L, Maldonado F, Greillier L, et al: Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications. J Thorac Oncol 6:592–597, 2011.

Sarkar S, Bhattacharya G, Bhattacharjee S, et al: A drop of hydrogen peroxide can differentiate exudative pleural effusion from transudate--development of a bedside screening test. Clin Chim Acta 405:83–86, 2009.

Schneider T, Reimer P, Storz K, et al: Recurrent pleural effusion: Who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg 57:42–46, 2009.

Schniewind B, Rose T, Woltmann N, et al: Clinical outcomes and health-related quality of life after thoracoscopic talc pleurodesis. J Palliat Med 15:37–42, 2012.

Stathopoulos GT, Kalomenidis I: Malignant pleural effusion: Tumor-host interactions unleashed. Am J Respir Crit Care Med 186:487-492, 2012.

Steger V, Mika U, Toomes H, et al: Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 83:1940–1945, 2007.

Tamiya M, Tamiya A, Yamadori T, et al: Phase 2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol 30:676, 2013.

Tan C, Sedrakyan A, Browne J, et al: The evidence on the effectiveness of management for malignant pleural effusion: A systematic review. Eur J Cardiothorac Surg 29: 829–838, 2006.

Thornton RH, Miller Z, Covey AM, et al: Tunneled pleural catheters for treatment of recurrent malignant pleural effusion following failed pleurodesis. J Vasc Interv Radiol 21:696–700, 2010.

Tremblay A, Mason C, Michaud G: Use of tunnelled pleural catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J 30:759–762, 2007.

Tsai TH, Wu SG, Chang YL, et al: Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 7:993–1000, 2012.

Vignon P, Dugard A, Abraham J, et al: Focused training for goal-oriented hand-held echocardiography performed by noncardiologist residents in the intensive care unit. Intensive Care Med 33:1795–1799, 2007.

Warren WH, Kalimi R, Khodadadian LM, et al: Management of malignant pleural effusions using the Pleur (x) catheter. Ann Thorac Surg 85:1049–1055, 2008.

William WN Jr, Lin HY, Lee JJ, et al: Revisiting stage IIIB and IV non-small cell lung cancer: Analysis of the surveillance, epidemiology, and end results data. Chest 136:701–709, 2009.

On Pericardial Effusion

Cullinane CA, Paz IB, Smith D, et al: Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 125:1328–1334, 2004.

Fukada J, Shigematsu N, Takeuchi H, et al: Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Rad Onc Biol Phys 87:487–493, 2013.

Kühn B, Peters J, Marx GR, et al: Etiology, management, and outcome of pediatric pericardial effusions. Pediatr Cardiol 29:90–94, 2008.

Kunitoh H, Tamura T, Shibata T, et al: A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 100:464–469, 2009.

Maisch B, Seferovic PM, Ristic AD, et al: Guidelines on the diagnosis and management of pericardial diseases executive summary: The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Eur Heart J 25:587–610, 2004.

Marcy PY, Bondiau PY, Brunner P: Percutaneous treatment in patients presenting with malignant cardiac tamponade. Eur Radiol 15:2000–2009, 2005.

McDonald JM, Meyers BF, Guthrie TJ, et al: Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion. Ann Thorac Surg 76:811–816, 2003.

Neragi-Miandoab S, Linden PA, Ducko CT, et al: VATS pericardiotomy for patients with known malignancy and pericardial effusion: Survival and prognosis of positive cytology and metastatic involvement of the pericardium: A case control study. Int J Surg 6:110–114, 2008.

Patel N, Rafique AM, Eshaghian S, et al: Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy. Am J Cardiol 112:1235–1239, 2013.

Restrepo CS, Lemos DF, Lemos JA, et al: Imaging findings in cardiac tamponade with emphasis on CT. Radiographics 27:1595–1610, 2007.

Romano EJ, Glass PS: Laparoscopic pericardial window: Anesthetic implications. J Cardiothorac Vasc Anesth 16:623–625, 2002.

Sagristà-Sauleda J, Angel J, Sambola A, et al: Hemodynamic effects of volume expansion in patients with cardiac tamponade. Circulation 117:1545–1549, 2008.

Szturmowicz M, Tomkowski W, Fijalkowska A, et al: Diagnostic utility of CYFRA 21-1 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis. Int J Biol Markers 20:43–49, 2005.

Swanson N, Mirza I, Wijesinghe N, et al: Primary percutaneous balloon pericardiotomy for malignant pericardial effusion. Catheter Cardiovasc Interv 71:508–509, 2008.

Tomkowski WZ, Wisniewska J, Szturmowicz M, et al: Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer 12:53–57, 2004.

Toth I, Szucs G, Molnar TF: Mediastinoscope-controlled parasternal fenestration of the pericardium: definitive surgical palliation of malignant pericardial effusion. J Cardiothorac Surg 7:56, 2012.

Tsang TS, Enrique-Sarano M, Freeman WK, et al: Consecutive 1,127 therapeutic echocardiographically guided pericardiocenteses: Clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 77:429–436, 2002.

Wagner PL, McAleer E, Stillwell E, et al: Pericardial effusions in the cancer population: Prognostic factors after pericardial window and the impact of paradoxical hemodynamic instability. J Thorac Cardiovasc Surg 141:34–38, 2011.

On Malignant Ascites

Barni S, Cabiddu M, Ghilardi M, et al: A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol 79:144–153, 2011.

Cavazzoni E, Bugiantella W, Graziosi L, et al: Malignant ascites: Pathophysiology and treatment. Int J Clin Oncol 18:1–9, 2013.

Diaz JP, Abu-Rustum NR, Sonoda Y, et al: Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol 116:483–488, 2010.

Eskander RN, Tewari KS: Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol 5(Suppl 1):55–61, 2013.

Keen A, Fitzgerald D, Bryant A, et al: Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev 1:CD007794, 2010.

Kim KW, Choi HJ, Kang S, et al: The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. Eur J Radiol 75:230–235, 2010.

Li CP, Huang TS, Chao Y, et al: Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies. World J Gastroenterol 10:2468–2471, 2004.

Nazeer SR, Dewbre H, Miller AH: Ultrasound-assisted paracentesis performed by emergency physicians vs the traditional technique: A prospective, randomized study. Am J Emerg Med 23:363–367, 2005.

Sangisetty SL, Miner TJ: Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 4:87–95, 2012.

Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36:458–467, 2010.

White J, Carolan-Rees G: PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: A NICE Medical Technology Guidance. Appl Health Econ Health Policy 10:299–308, 2012.